Written by Klarity Editorial Team
Published: Jun 11, 2026

Disclaimer: All prescribing decisions are made by licensed healthcare providers based on individual clinical evaluation. Nothing in this article guarantees a prescription. Treatment decisions vary by patient history, state law, and provider assessment.
Cerebral halted Adderall prescriptions for new patients in mid-2022 following a DEA investigation and has not publicly confirmed a full return to stimulant prescribing. Telehealth providers with DEA-registered prescribers can prescribe Adderall online in most U.S. states under federal flexibilities extended through 2026, subject to a clinical evaluation. Klarity Health connects patients with 2,000+ licensed providers who may evaluate ADHD and, when appropriate, prescribe stimulant medications — with same-week appointments available in all 50 states.
Cerebral's current stance on Adderall prescriptions is complicated by regulatory history. In May 2022, the U.S. Department of Justice opened an investigation into Cerebral for possible violations of the Controlled Substances Act, specifically scrutinizing how the platform prescribed stimulant medications to new ADHD patients. Shortly after, Cerebral announced it would stop writing Adderall, Ritalin, and other stimulant prescriptions for new patients.
Cerebral later agreed to pay over $3.6 million to resolve related business practice concerns. While the platform has continued to evolve its clinical model, patients researching Cerebral for ADHD stimulant treatment face real uncertainty about what is currently available to them.
If you need an ADHD evaluation and are considering whether stimulant medication may be part of your treatment plan, you are better served by a platform with a clear, active clinical pathway for ADHD management. This article explains what to know.
Cerebral became one of the most prominent telehealth companies targeted during a federal review of online stimulant prescribing practices. The company faced scrutiny from the DEA after reports surfaced that:
Cerebral stopped prescribing Adderall, Ritalin, and other Schedule II stimulants to new patients while the investigation proceeded — a halt that affected hundreds of thousands of patients who had signed up expecting medication management for ADHD.
Cerebral eventually agreed to pay over $3.6 million in connection with the investigation. While the company denied certain allegations, the settlement and the preceding halt in stimulant prescribing left a lasting mark on patient trust and on the platform's clinical model.
Cerebral's blog has not published new ADHD content since October 2024. The platform's current prescribing practices for Schedule II stimulants are not clearly documented in public-facing materials, which is why so many patients are searching "does Cerebral prescribe Adderall" in 2026 — and why the answer remains genuinely unclear without direct inquiry to the platform.
Adderall (amphetamine salts) is a Schedule II controlled substance under the Controlled Substances Act. For most of U.S. history, prescribing Schedule II medications required an in-person visit. COVID-era telehealth flexibilities changed that.
Under current federal rules, a DEA-registered practitioner may prescribe Schedule II controlled substances via telehealth without a prior in-person visit, provided specific conditions are met. Those federal flexibilities remain active through 2026 for most states.
What this means for patients:
Important caveat: A prescription is not guaranteed. Providers make prescribing decisions based on individual clinical assessment, your medical history, current medications, and applicable state law. Patients with a history of substance use disorder, cardiovascular conditions, or certain other factors may be directed toward non-stimulant options first.
New Jersey changed its rules effective February 16, 2026. Per the American Psychiatric Association, New Jersey now requires an initial in-person examination before Schedule II stimulants can be prescribed via telehealth, with a follow-up in-person visit at least every three months. If you are in New Jersey, confirm current state requirements with your provider before booking.
Given what happened with Cerebral, patients evaluating telehealth platforms for ADHD care should ask specific questions:
1. Does the platform have active DEA-registered prescribers?
Not all telehealth providers have prescribers registered with the DEA for Schedule II medications. Confirm before booking.
2. What does the ADHD evaluation include?
A thorough ADHD assessment should include a detailed symptom history, review of prior diagnoses or treatment, and discussion of how symptoms affect daily functioning. Be cautious of any platform that skips this.
3. Can the provider prescribe both stimulant and non-stimulant options?
Adderall and Vyvanse are not the right fit for every patient. Platforms with access to the full range of ADHD medications — stimulants, non-stimulants like Strattera, and long-acting options — give you more flexibility if first-line treatment does not work well.
4. Does the platform accept your insurance?
ADHD evaluations and medication management visits may be covered by many insurance plans. Confirm whether the platform accepts your insurer before booking, as coverage varies by plan.
5. How fast can you get an appointment?
ADHD symptoms affect work, relationships, and quality of life. A platform with same-week availability matters — not one with a six-week waitlist.
Adderall is one of several first-line options for ADHD. If stimulants are not appropriate for you — or if your provider recommends starting elsewhere — the following medications are also commonly evaluated and managed online:
| Medication | Type | Key Characteristic |
|---|---|---|
| Vyvanse (lisdexamfetamine) | Stimulant (Schedule II) | Longer duration, lower abuse potential |
| Ritalin / Concerta (methylphenidate) | Stimulant (Schedule II) | Different mechanism than amphetamines |
| Strattera (atomoxetine) | Non-stimulant | No abuse potential; takes 4-6 weeks for full effect |
| Wellbutrin (bupropion) | Non-stimulant (antidepressant) | Off-label ADHD use; may also address comorbid depression |
| Intuniv / Kapvay (guanfacine, clonidine) | Non-stimulant | Often used for children or in combination |
A complete ADHD medication guide can help you understand the differences before your appointment.
Telehealth ADHD prescribing rules vary. Most states continue to allow online stimulant prescriptions under federal flexibilities, but local regulations can affect specific medications, follow-up requirements, and prescriber licensing rules.
Key considerations:
Klarity Health connects patients with 2,000+ licensed providers across all 50 states. If your clinical evaluation supports an ADHD diagnosis and stimulant treatment, your provider may prescribe Adderall, Vyvanse, or other appropriate medications — with the prescription sent electronically to a pharmacy of your choice.
How the process works:
Most major insurance plans may cover telehealth ADHD visits. Coverage varies by plan; verify your benefits before booking.
Book an ADHD evaluation with Klarity
Does Cerebral still prescribe Adderall in 2026?
Cerebral halted stimulant prescriptions for new patients in 2022 following a DEA investigation. The platform's current prescribing practices for new patients seeking Adderall are not clearly documented in public materials. If you need an active ADHD treatment pathway, a platform with a clear and uninterrupted clinical model for stimulant prescribing may be a better option.
Can you get Adderall online without an in-person visit?
In most U.S. states, yes — under federal telehealth flexibilities active through 2026. A DEA-registered provider may prescribe Adderall via video appointment after completing a clinical evaluation. New Jersey is an exception as of February 2026, requiring an initial in-person visit.
Is it legal to prescribe Adderall via telehealth?
Yes, in most states under current federal rules. The DEA permits Schedule II controlled substance prescriptions via telehealth when specific criteria are met, including a real-time audio-visual appointment with a licensed, DEA-registered provider.
What happens if Adderall is not the right option for me?
Your provider may recommend non-stimulant ADHD medications like Strattera (atomoxetine), Wellbutrin, or guanfacine. These carry no Schedule II classification and may be a better fit based on your health history. A thorough evaluation will help your provider make the right recommendation.
How do I know if my insurance covers an online ADHD evaluation?
Insurance coverage for telehealth varies by plan. Many plans may cover evaluation and medication management visits — check with your insurer before booking. Klarity accepts major insurance plans, with cash-pay options also available.
All professional services on Klarity Health are provided by independent private practices via the Klarity technology platform. Klarity Health, Inc. does not provide medical services. Prescribing decisions are made solely by your licensed provider based on individual clinical assessment.
Find the right provider for your needs — select your state to find expert care near you.